Macrogenics Stock Price, News & Analysis

MacroGenics, Inc. (MGNX) stock represents a biopharmaceutical company focused on monoclonal antibody-based therapeutics for cancer. According to company disclosures, MacroGenics discovers, develops, manufactures and in some cases commercializes antibody-based medicines for oncology, using proprietary technology platforms and protein engineering expertise to generate its pipeline of product candidates.

The company describes itself as a biopharmaceutical organization focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline primarily from a proprietary suite of next-generation antibody-based technology platforms, which it states have applicability across broad therapeutic domains. This platform approach, together with internal protein engineering capabilities, has enabled MacroGenics to advance multiple investigational programs and enter into strategic collaborations with other pharmaceutical and biotechnology companies.

Core focus: antibody-based cancer therapeutics

MacroGenics reports that its work centers on antibody-based therapeutics, including monoclonal antibodies, bispecific molecules and antibody-drug conjugates (ADCs). The company highlights several proprietary investigational programs:

• Lorigerlimab, described as a bispecific, tetravalent PD-1 × CTLA-4 DART^® molecule designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes while maintaining PD-1 blockade on PD-1–expressing cells. MacroGenics is evaluating lorigerlimab in clinical studies, including the LORIKEET and LINNET Phase 2 trials in oncology indications such as metastatic castration-resistant prostate cancer and certain gynecologic cancers, as outlined in its press releases.
• Antibody-drug conjugates (ADCs) that incorporate a novel, glycan-linked topoisomerase I inhibitor (TOP1i)-based payload developed with collaboration partner Synaffix (a Lonza company). The company identifies three ADC candidates: MGC026, targeting B7-H3; MGC028, targeting ADAM9; and MGC030, a preclinical ADC directed to an undisclosed antigen expressed across several solid tumors.
• MGD024, a next-generation CD123 × CD3 DART molecule being advanced under an exclusive option and collaboration agreement with Gilead Sciences, Inc., in a Phase 1 dose escalation study in CD123-positive hematologic malignancies.

MacroGenics also notes that it has participated in the development of approved products that are now partnered, such as ZYNYZ^® (retifanlimab-dlwr), a monoclonal antibody targeting PD‑1 licensed to Incyte Corporation, and TZIELD^® (teplizumab-mzwv), a monoclonal antibody targeting CD3 that was sold to a partner later acquired by Sanofi S.A. The company reports that it remains eligible for milestone payments related to these partnered programs and that it supports a portion of global commercial manufacturing needs for ZYNYZ.

Business activities and collaborations

In its public communications, MacroGenics emphasizes several recurring themes in its business model:

• Discovery and development of monoclonal antibody-based therapeutics for cancer, including bispecific DART molecules and ADCs generated from its technology platforms.
• Manufacturing capabilities, including contract manufacturing revenue from production on behalf of contract development and manufacturing organization (CDMO) clients, as reflected in its financial results disclosures.
• Strategic collaborations with global pharmaceutical and biotechnology companies. Examples cited by the company include collaboration and license agreements with Gilead Sciences, Incyte and arrangements related to TZIELD with a partner later acquired by Sanofi.
• Royalty and milestone economics from partnered programs, including royalty purchase and milestone structures described in its press releases regarding ZYNYZ and TZIELD.

The company repeatedly states that the combination of its antibody-based technology platforms and protein engineering expertise has allowed it to generate promising product candidates and to enter into several strategic collaborations. It also highlights that it has implemented cost-reduction initiatives and evaluates monetization of assets and collaboration revenue as part of its financial planning, as reflected in its financial results updates.

Pipeline highlights mentioned by the company

Based on MacroGenics’ own descriptions in its news releases:

• Lorigerlimab is being studied in oncology indications. The LORIKEET Phase 2 trial evaluates lorigerlimab in combination with docetaxel in metastatic castration-resistant prostate cancer, and the LINNET Phase 2 study evaluates lorigerlimab monotherapy in platinum-resistant ovarian cancer and clear cell gynecologic cancer. The company has indicated that it decided not to pursue further development of lorigerlimab in second-line metastatic castration-resistant prostate cancer after reviewing interim data, while continuing development in gynecologic cancers.
• MGC026 targets B7-H3, which MacroGenics describes as an antigen with broad expression across multiple solid tumors and a member of the B7 family of molecules involved in immune regulation. The company reports that MGC026 is in Phase 1 dose escalation, with dose expansion initiated or planned in selected solid tumor indications.
• MGC028 targets ADAM9, which MacroGenics characterizes as a multifunctional transmembrane protein associated with tumorigenesis and cancer progression and overexpressed in multiple cancers. The company notes that a Phase 1 study in advanced solid tumors is ongoing and that preclinical data have shown antitumor activity and an acceptable safety profile.
• MGC030 is described as a preclinical ADC targeting an undisclosed antigen expressed across several solid tumors, with no approved therapeutics to that target according to the company. MacroGenics has indicated plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration for MGC030.
• MGD024, under collaboration with Gilead, is in a Phase 1 dose escalation study for CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes, as described in MacroGenics’ updates.

Partnered products and financial arrangements

MacroGenics’ disclosures describe several partnered products and financial structures:

• ZYNYZ^® (retifanlimab-dlwr), a PD‑1–targeting monoclonal antibody licensed to Incyte. The company reports that ZYNYZ is indicated in the United States for certain patients with squamous cell carcinoma of the anal canal and metastatic or recurrent locally advanced Merkel cell carcinoma, and that it has entered into a royalty purchase agreement with Sagard Healthcare Partners involving a capped royalty interest on future global net sales of ZYNYZ.
• TZIELD^® (teplizumab-mzwv), a monoclonal antibody targeting CD3 that MacroGenics sold in 2018 to a partner later acquired by Sanofi. The company notes that TZIELD has U.S. Food and Drug Administration approval to delay the onset of Stage 3 type 1 diabetes in certain patients and that MacroGenics remains eligible for additional development, regulatory and commercial milestones.

MacroGenics’ financial updates reference revenue from collaborative and other agreements, contract manufacturing, and, historically, product sales prior to the sale of MARGENZA commercialization rights. The company also discusses cash runway expectations, cost-reduction initiatives and partnering proceeds from agreements with counterparties such as Gilead, Sanofi and Sagard Healthcare Partners.

Leadership and governance updates

SEC filings and company press releases describe changes in senior leadership. An August 2025 Form 8‑K and accompanying press release note the appointment of Eric Risser as President, Chief Executive Officer and director, succeeding the prior CEO. Another Form 8‑K filed in November 2025 reports the planned departure of the Senior Vice President, Clinical Development and Chief Medical Officer and the interim assumption of oversight of clinical development by another executive, while the company conducts a search for a new Chief Medical Officer.

Stock listing and sector classification

MacroGenics states in multiple releases that its common stock trades on Nasdaq under the ticker symbol MGNX. The industry classification provided identifies the company within pharmaceutical preparation manufacturing in the broader manufacturing sector. In its own descriptions, MacroGenics consistently characterizes itself as a biopharmaceutical or clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for cancer.

How investors may use MacroGenics information

Investors researching MGNX stock often review the company’s oncology pipeline, technology platforms, partnered programs and collaboration economics as described in MacroGenics’ press releases and SEC filings. Company communications highlight key strategic priorities related to pipeline development, partnerships, financial planning and cost management. These disclosures, together with regulatory filings such as Forms 8‑K, provide detail on clinical programs, collaboration agreements, executive leadership changes and selected financial information.